Cargando…
A Phase I Randomized Trial of Once‐Daily Versus Twice‐Daily Recombinant Human Parathyroid Hormone (1‐84) for Hypoparathyroidism
Recombinant human parathyroid hormone (1‐84), rhPTH(1‐84), is an approved adjunctive treatment to oral calcium and active vitamin D for adult patients with hypoparathyroidism; however, there is limited information on the effect of twice daily (BID) dosing of rhPTH(1‐84). This was a phase I, open‐lab...
Autores principales: | Ing, Steven W., Finkelman, Richard D., He, Ping, Khan, Aliya A., Mannstadt, Michael, Rejnmark, Lars, Song, Ivy, Takács, István, Wu, Yuna |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10339078/ https://www.ncbi.nlm.nih.gov/pubmed/37457880 http://dx.doi.org/10.1002/jbm4.10758 |
Ejemplares similares
-
Long-Term Safety and Efficacy of Recombinant Human Parathyroid Hormone (1-84) in Adults With Chronic Hypoparathyroidism
por: Watts, Nelson B, et al.
Publicado: (2023) -
Hypoparathyroidism: Replacement Therapy with Parathyroid Hormone
por: Rejnmark, Lars, et al.
Publicado: (2015) -
Therapy of Hypoparathyroidism by Replacement with Parathyroid Hormone
por: Rejnmark, Lars, et al.
Publicado: (2014) -
OR30-1 Safety and Efficacy of Recombinant Human Parathyroid Hormone 1-84 for the Treatment of Adults with Chronic Hypoparathyroidism: Six-Year Results of the RACE Study
por: Bilezikian, John, et al.
Publicado: (2019) -
Effects of parathyroid hormone rhPTH(1–84) on phosphate homeostasis and vitamin D metabolism in hypoparathyroidism: REPLACE phase 3 study
por: Clarke, Bart L., et al.
Publicado: (2016)